KEYNOTE-042: 5-year update of first-line pembrolizumab in Asian patients with locally advanced/metastatic PD-L1-positive NSCLC-MedSci.cn

KEYNOTE-042: 5-year update of first-line pembrolizumab in Asian patients with locally advanced/metastatic PD-L1-positive NSCLC

Kubota, K; Cho, BC; Srimuninnimit, V; Fan, Y; Zhou, JY; Zhang, L; Zhou, Q; Hosomi, Y; Takeoka, H; Mukherjee, R; Fu, W; Souza, F; Mok, TSK; Zhang, L

ANNALS OF ONCOLOGY, 2022; 33 (): S472

科室
- - 订阅+
  - 更多科室
工具
服务